Antimicrobial Resistance Project BioShield: BARDA Antibiotic for AMR and Biothreat Pathogens

This pre-solicitation notice seeks proposals to support the late-stage development and regulatory approval of an antibiotic to treat infections caused by Yersinia pestis, Francilla tularensis, or Burkholderia pseudomallei. The Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response intends to procure the antibiotic through Project BioShield to deliver to the Strategic National Stockpile or maintain as vendor-managed inventory. BARDA may award multiple cost-plus-fixed-fee or firm-fixed-price contracts from the anticipated January 2022 solicitation, with an expected period of performance up to 120 months on any resulting contract. All respondents must register in the System for Award Management, and the notice provides points of contact for questions before the January 3, 2022 deadline.

The set-aside is designated for total small business. The anticipated NAICS codes are 541711 for research and development in biotechnology, and 339112 for surgical and medical instrument manufacturing. There is no mention of incumbent contractors. Potential awards are not specified, but the period of performance on any contract could be up to 120 months. The antibiotic procured must treat infections from the listed biothreat pathogens and be delivered to the Strategic National Stockpile or maintained as vendor-managed inventory.